VKTX
Viking TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive clinical readouts or a strategic partnership meaningfully de‑risk programs and push valuation toward premium biotech multiples (~$58/share).
Posture
Constructive
Lead driver
Momentum
What changed
Next scheduled catalyst: earnings 2026-07-21 · AMC.
What can break
Trial failures, persistent cash burn, or dilutive financing compress valuation toward the low‑twenties (~$23/share).
Momentum
93
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.55 · Bull $57.83 · Bear $23.13
Earnings
2026-07-21 · AMC
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $94.29
Why
Momentum93 · Δ7d -3.1
Value41 · Δ7d -0.1
Sentiment52 · Δ7d +1.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
+44.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
52
34% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+0.8
Why this grade
Composite grade B. Momentum 93.0 / Value 41.1 / Sentiment 51.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.31B
Beta
0.76
Shares Out
116.11M
P/E (TTM) · Derived
-11.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.40
Rev YoY
-
EPS YoY
+236.4%
Gross Margin
-
Op Margin
-
Net Debt
-$705.6M
Current Ratio
5.72
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology